RESUMEN
BACKGROUND: Gastric precancerous lesion (GPL) is a necessary stage in the occurrence and development of gastric cancer. At present, the incidence of gastric cancer is increasing year by year. It is important to prevent and control gastric cancer through early detection and intervention. Banxia Xiexin Decoction (BXD) has a good effect in improving symptoms, reducing inflammation, promoting the repair of gastric mucosa, reversing its atrophy and intestinal metaplasia. BXD may be a foreground choice for the treatment of GPL. METHODS: Randomized controlled trials of BXD for GPL will be searched in the relevant database, including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Biomedical Literature Database (CBM), and Chinese Scientific Journal Database (VIP database). The studies of electronic searches will be exported to EndNote V.9.1 software. We will run meta-analyses using the Review Manager (RevMan) V.5.3 software. Any disagreement will be solved in consultation with a third reviewer. RESULTS: Our study aims to explore the efficacy of BXD for GPL and to provide up-to-date evidence for clinical of GPL. CONCLUSION: The conclusion of this study will provide evidence for the efficacy of BXD on GPL. INPLASY REGISTRATION NUMBER: INPLASY 202130102.
Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Neoplasias Intestinales/tratamiento farmacológico , Lesiones Precancerosas/tratamiento farmacológico , Neoplasias Gástricas/tratamiento farmacológico , Enfermedad Crónica , Femenino , Gastritis Atrófica/complicaciones , Gastritis Atrófica/tratamiento farmacológico , Humanos , Enfermedades Intestinales/complicaciones , Enfermedades Intestinales/tratamiento farmacológico , Neoplasias Intestinales/etiología , Masculino , Metaanálisis como Asunto , Lesiones Precancerosas/etiología , Ensayos Clínicos Controlados Aleatorios como Asunto , Proyectos de Investigación , Neoplasias Gástricas/etiología , Revisiones Sistemáticas como Asunto , Resultado del TratamientoRESUMEN
BACKGROUND: Acute gouty arthritis is a joint inflammatory reaction that affects the daily quality of patients. Previous reviews of pricking-blood therapy for acute gouty arthritis have been growing, but a systematic review is not available. This study aimed to systematically investigate the efficacy and safety of pricking-blood therapy in treating acute gout arthritis. METHODS: We will search for relevant literature through Chinese and English databases, with the retrieval deadline being December 2020. Databases include PubMed, Embase, Web of Science, the Cochrane Library, China National Knowledge Infrastructure, the Chongqing VIP Chinese Science and Technology Periodical Database, Wanfang Database, and China Biomedical Literature Database. We will also manually search Chinese Acupuncture & Moxibustion, Acupuncture Research, Chinese Clinical Trial Register, and unpublished studies or references. According to the inclusion and exclusion criteria, the literature will be screened, and the data are extracted independently by the 2 researchers. The primary outcomes were the total effective rate and Visual Analogue Scale (VAS) score. RevMan 5.3.5. software will be used for statistical analysis. According to the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE), each evidence of outcome quality will be appraised. RESULTS: This study will provide a comprehensive review of current evidence for a pricking-blood therapy treatment for acute gouty arthritis. CONCLUSION: The efficacy and safety of picking-blood therapy in treating acute gout arthritis will be evaluated. UNIQUE INPLASY NUMBER: INPLASY2020100094.